- Urinary tract infections
- Lower respiratory tract infections
- Skin and skin structure infections
- Gynecologic infections, including PID (note: no activity against C. trachomatis)
- No longer recommended in 2022 STD Guideline.
- Intra-abdominal infections (IDSA guidelines: cefotetan is no longer recommended for intra-abdominal infections as monotherapy due to high rates of B. fragilis resistance).
- Bone and joint infections (author’s comment: generally used for mild infections)
- Surgical prophylaxis (e.g., cesarean section, abdominal or vaginal hysterectomy, trans-urethral surgery, biliary tract surgery, and gastrointestinal surgery)
NON-FDA APPROVED USES
- Uncomplicated cholangitis
There's more to see -- the rest of this topic is available only to subscribers.